Living with a prostate cancer diagnosis often comes with the constant worry of whether the cancer will return. Researchers have identified a specific three-gene risk score involving EZH2, CDK1, and AURKA that may help predict this outcome more accurately. By looking at these specific genes, the model can help identify patients who might need closer monitoring or different treatment paths.
The study looked at 554 samples and found that patients with a high risk score had much worse survival rates when it came to staying free from biochemical recurrence. This means the test is designed to flag high-risk cases early. The study also looked at the immune environment around these tumors, finding that high-risk tumors had fewer immune cells and more markers that could potentially be targeted by future therapies.
While these results are promising for identifying risk, it is important to note that this research involved computer modeling and cell line testing rather than a clinical trial on patients. Because of this, the findings are currently a tool for identifying risk and potential targets, not a confirmed new treatment. Talk to your doctor about how these genetic markers might relate to your specific diagnosis.
